Active Ingredient History
Oxcarbazepine and its active metabolite (10,11-dihydro-10-hydroxy-carbazepine, MHD) have been effective in animal models of epilepsy that generally predict efficacy in generalized tonic-clonic seizures and partial seizures in humans. The pharmacokinetic profile of oxcarbazepine is less complicated than that of carbamazepine, with less metabolism by the cytochrome P450 system, no production of an epoxide metabolite, and lower plasma protein binding. The clinical efficacy and tolerability of oxcarbazepine have been demonstrated in trials in adults, children, and the elderly. The pharmacological activity of oxcarbazepine is primarily exerted through the 10-monohydroxy metabolite (MHD) of oxcarbazepine. The precise mechanism by which oxcarbazepine and MHD exert their antiseizure effect is unknown; however, in vitro electrophysiological studies indicate that they produce blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of synaptic impulses. These actions are thought to be important in the prevention of seizure spread in the intact brain. In addition, increased potassium conductance and modulation of high-voltage activated calcium channels may contribute to the anticonvulsant effects of the drug. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Anxiety (Phase 3)
Anxiety Disorders (Phase 3)
Asthma (Phase 4)
Astrocytoma (Phase 1)
Bipolar Disorder (Phase 4)
Conduct Disorder (Phase 4)
Dementia (Phase 3)
Depression (Phase 3)
Drug Resistant Epilepsy (Phase 4)
Epilepsies, Partial (Phase 4)
Epilepsy ()
Glioblastoma (Phase 1)
Glioma (Phase 4)
Gliosarcoma (Phase 1)
Healthy Volunteers (Phase 1)
Intellectual Disability (Phase 4)
Metabolic Clearance Rate (Phase 4)
Multiple Sclerosis (Phase 2)
Neoplasms (Phase 1)
Neuralgia (Phase 4)
Neuralgia, Postherpetic (Phase 4)
Oligodendroglioma (Phase 1)
Peripheral Nerve Injuries (Phase 4)
Polyneuropathies (Phase 4)
Psychophysiologic Disorders (Phase 3)
Schizophrenia (Phase 3)
Seizures (Phase 4)
Spinal Cord Injuries (Phase 4)
Treatment Outcome (Phase 4)
Trigeminal Neuralgia (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
